PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Luteinization”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 991 records · Page 55Linked to original sources

Prostaglandin F2 alpha, oxytocin and progesterone secretion by bovine luteal cells at several stages of luteal development: effects of oxytocin, luteinizing hormone, prostaglandin F2 alpha and estradiol-17 beta.

Bovine luteal cells from Days 4, 8, 14 and 18 of the estrous cycle were incubated for 2 h (1 x 10(5) cells/ml) in serum-free media with one or a combination of treatments [control (no hormone), prostaglandin F2 alpha (PGF), oxytocin (OT), estradiol-17 beta (E) or luteinizing hormone (LH)]. Luteal cell conditioned media were then assayed by RIA for progesterone (P), PGF, and OT. Basal secretion of PGF on Days 4, 8, 14 and 18 was 173.8 +/- 66.2, 111.1 +/- 37.8, 57.7 +/- 15.4 and 124.3 +/- 29.9 pg/ml, respectively. Basal release of OT and P was greater on Day 4 (P less than 0.01) than on Day 8, 14 and 18 (OT: 17.5 +/- 2.6 versus 5.6 +/- 0.7, 6.0 +/- 1.4 and 3.1 +/- 0.4 pg/ml; P: 138.9 +/- 19.5 versus 23.2 +/- 7.5, 35.4 +/- 6.5 and 43.6 +/- 8.1 ng/ml, respectively). Oxytocin increased (P less than 0.01) PGF release by luteal cells compared with control cultures irrespective of day of estrous cycle. Estradiol-17 beta stimulated (P less than 0.05) PGF secretion on Days 8, 14 and 18, and LH increased (P less than 0.01) PGF production only on Day 14. Prostaglandin F2 alpha, E and LH had no effect on OT release by luteal cells from any day. Luteinizing hormone alone or in combination with PGF, OT or E increased (P less than 0.01) P secretion by cells from Days 8, 14 and 18. However on Day 8, a combination of PGF + OT and PGF + E decreased (P less than 0.05) LH-stimulated P secretion. These data demonstrate that OT stimulates PGF secretion by bovine luteal cells in vitro. In addition, LH and E also stimulate PGF release but effects may vary with stage of estrous cycle.

Animals↗

Active immunization of stumptailed macaque monkeys against luteinizing hormone releasing hormone, and its effects on menstrual cycles, ovarian steroids and positive feedback.

Five female stumptailed macaque monkeys with regular menstrual cycles were immunized against luteinizing hormone releasing hormone (LHRH) conjugated to tetanus toxoid. The conjugate was given in Freund's complete adjuvant (3 monkeys) or dipeptide adjuvant (2 monkeys). Only the 3 monkeys immunized using Freund's adjuvant produced LHRH antibody titres capable of having effects on menstrual cycles. Elevated levels of LHRH antibody were associated with an absence of preovulatory luteinizing hormone (LH) surges in serum and an inability to respond to an injection of oestradiol benzoate which produced an LH surge (positive feedback) in control animals. Cyclical rises in serum concentrations of follicle-stimulating hormone (FH) were also abolished when LHRH antibody levels were elevated. These effects on LH and FSH caused a reduction in serum concentrations of 17 beta-oestradiol and absence of progesterone rises indicating inhibition of follicular development and ovulation, which resulted in amenorrhoea. Time to decline of LHRH antibody titres leading to re-establishment of menstrual cycles varied but could be reversed by booster immunizations.

Animals↗

Facilitation of mounting behavior in male rats by intracranial injections of luteinizing hormone-releasing hormone.

Luteinizing hormone-releasing hormone (LH-RH) administration has been reported to facilitate male sex behavior. This laboratory has previously reported development of the 'mounting test', a paradigm which reflects sexual arousal mechanisms. We have used this test to study the interaction of LH-RH with the central components of male copulatory behavior in the rat. Sixty 90-day-old Long-Evans male rats were screened for sex behavior and divided into 5 treatment groups. For all mounting tests, a local anesthetic was applied to the penis and mounts were scored during a 15-min exposure to a stimulus female. The animals were given 3 successive weekly tests. By the final test, a significant decrement in mounting behavior was noted, and those males given 50 ng LH-RH i.c.v. displayed more mounting in this test than animals given either no treatment or saline (P less than 0.01). A slight but significant (P less than 0.05) enhancement of performance was also noted in peptide-treated rats in test I. There was no significant difference in any of the tests between animals given lateral cerebroventricular (i.c.v.) injections of 2 microliter acidified saline and those given no treatment. When blood samples were taken from similarly treated animals and assayed by radioimmunoassay for luteinizing hormone and testosterone, plasma levels of these hormones were not different at either 30 min or 2 h after injection of saline or LH-RH. Thus, in animals with diminished genital sensory input, LH-RH administration increases mounting behavior without inducing measurable reproductive endocrine changes. It is proposed that this effect results from an interaction of this peptide with the neural substrates of the arousal mechanism.

Animals↗

Molecular dynamics of luteinizing hormone receptors on rat luteal cells.

To better understand the in situ organization of the luteinizing hormone receptor on rat luteal cells, we have examined the molecular motions of this receptor following binding of ovine luteinizing hormone (oLH) or human chorionic gonadotropin (hCG). Fluorescence photobleaching recovery (FPR) measurements of LH receptor lateral diffusion were performed using tetramethylrhodamine isothiocyanate (TRITC)-derivatized oLH or hCG as a probe. These experiments indicate that TRITC-oLH occupied LH receptors on luteal cells obtained from superovulated female rats have a lateral diffusion coefficient D of (1.7 +/- 0.6).10(-10) cm2s-1 at 27 degrees C with fluorescence recovery after photobleaching of 46 +/- 5%. In similar experiments, binding of TRITC-hCG caused a significant decrease in LH receptor lateral diffusion; fluorescence recovery after photobleaching was less than 20%. To determine whether hCG-occupied receptors might exist in large aggregates, we measured the rotational correlation times (RCT) of hCG and oLH bound to the LH receptor on intact cells using single cell polarized fluorescence depletion (PFD). At 4 degrees C, LH receptors occupied by eosin isothiocyanate (EITC)-hCG exhibited a slower RCT (64 microseconds) than did receptors occupied by EITC-oLH (43 microseconds). At this temperature both TRITC-oLH and TRITC-hCG occupied LH receptors were laterally immobile. These FPR and PFD results suggest that the molecular motions of the luteal cell LH receptor are significantly modulated by the subtle structural differences in various bound gonadotropins.

Animals↗

Synthesis and biological activity of [D-Trp6] chicken luteinizing hormone-releasing hormone.

An agonist of chicken hypothalamic luteinizing hormone-releasing hormone (cLH-RH), [D-Trp6] cLH-RH, was synthesized and tested for luteinizing hormone (LH)-releasing activity using dispersed chicken anterior pituitary cells, as well as for binding to rat anterior pituitary membrane receptors. cLH-RH and mammalian LH-RH (mLH-RH) gave identical dose-response curves in stimulating chicken LH release (ED50 = 1.6 and 1.8 X 10(-9) M respectively) and similar estimates of potency. The [D-Trp6] analogs of cLH-RH and mLH-RH stimulated LH release at lower doses (ED50 = 7.0 and approximately 7.0 X 10(-11) M respectively) and were approximately 20-fold more potent. In contrast to the activity in the chicken bioassay, cLH-RH bound to rat anterior pituitary membrane receptors with a much lower affinity than did mLH-RH and had a relative potency of 2%. [D-Trp6] cLH-RH was approximately 100-fold more potent than cLH-RH in the rat receptor assay while [D-Trp6] mLH-RH was 28-fold more active than mLH-RH. These data demonstrate that substitution of Gly6 of LH-RH with D-Trp enhances the LH release from chicken pituitary cells to a similar extent to that observed in mammals, and indicate that the approaches used to produce active LH-RH analogs in mammals are likely to be applicable to birds.

Animals↗

Effects of luteinizing hormone releasing hormone on gonadotrophins in the hamster.

The changes in serum gonadotrophins in male hamsters following one injection of 15 micrograms luteinizing hormone releasing hormone (LHRH) (Group A) were compared with those following the last injection of LHRH in animals receiving an injection approximately every 12 hr for 4 days (Group B) or 12 days (Group C). Peak follicle stimulating hormone (FSH) levels (ng/ml) were 1776 +/- 218 (Group A), 2904 +/- 346 (Group B), and 4336 +/- 449 (Group C). Peak luteinizing hormone (LH) values (ng/ml) were 1352 +/- 80 (Group A), 410 +/- 12 (Group B), and 498 +/- 53 (Group C). Serum FSH:LH ratios, calculated from the concentrations measured 16 hr after the last LHRH injections, were higher in Groups B and C than in Group A. Similar injections of LHRH (100 ng or 15 micrograms/injection) for 6 days elevated the serum FSH:LH ratio in intact males. Five such LHRH injections (100 ng/injection) blunted the rise in serum LH in orchidectomized hamsters. Direct effects of LHRH on gonadotrophin secretory dynamics or altered brain-pituitary-testicular interactions may alter the ratio of FSH to LH in the hamster.

Animals↗

Indomethacin decreases both luteinizing hormone binding and fluidity of testicular microsomal membranes in rat.

The objective of these studies was to examine the effects of in vivo treatment with indomethacin, a prostaglandin synthesis inhibitor, on luteinizing hormone receptors and fluidity in microsomal membrane preparations of rat testis. Adult male rats were treated with vehicle or either of two doses of indomethacin (3.8 micrograms/g body weight or 7.5 micrograms/g body weight) every 8 h for 1, 2 and 3 days. Indomethacin treatment decreased human luteinizing hormone (hLH) binding in rat testis in a time-dependent fashion. The lower dose of indomethacin decreased hLH binding by 19%, 35% and 50%, respectively, after 1, 2 and 3 days of treatment. The higher dose of indomethacin decreased hLH binding at these respective times by 21%, 44% and 56%. Scatchard analysis of the hLH binding of testicular membrane preparations indicated that indomethacin treatment decreased the number of hLH binding sites rather than the apparent affinity constant. Testicular membrane fluidity was estimated by a fluorescence polarization technique. The effects of indomethacin on apparent fluidity of microsomal membrane paralleled that of LH binding. The values of apparent microviscosity, inversely related to the fluidity, also increased in a time-dependent fashion. These simultaneous effects of indomethacin on testicular LH binding and fluidity suggest that these phenomena are interrelated and that prostaglandins are involved in the maintenance of LH receptors in vivo.

Animals↗

Seasonal variation in plasma testosterone, luteinizing hormone concentrations and LH-RH responsiveness in mature, male rusa deer (Cervus rusa timorensis).

Plasma testosterone and luteinizing hormone (LH) concentrations in immobilized or yarded rusa stags (Cervus rusa timorensis) were investigated over a two-year period. Testosterone concentrations showed a minor elevation in autumn (May) and reached maximal levels in late winter-early spring (August) coinciding with the rut. Luteinizing hormone in plasma was only detectable from January to May. Maximal responsiveness of the pituitary-gonadal axis to LH-RH stimulation was recorded in August. The combination of Fentaz (fentanylcitrate and azaperone) and Rompun (xylazine hydrochloride) for immobilizing deer influences hypothalamic function.

Acclimatization↗

Calcium as a second messenger in the stimulation of luteinizing hormone secretion.

In cells dissociated from porcine anterior pituitary glands and maintained in culture for 48 h the specific secretagogue luteinizing hormone-releasing hormone (LH-RH) induces a biphasic pattern of luteinizing hormone (LH) release. A biphasic pattern of release is also induced by 57 X 10(-3) M K+ and the ionophore A-23187. By reducing the availability of Ca2+, either by omission from the medium, chelation or interfering with Ca2+ transport across the plasma membrane, it is shown that LH release stimulated by LH-RH is much less dependent upon the availability of extracellular Ca2+ than that stimulated by either high K+ or A-23187. Nevertheless, by using a lanthanum displacement protocol to follow the influx of 45Ca2+ it is shown that LH-RH stimulation does induce an influx of extracellular Ca2+. Parallel experiments in which the stimulated 45Ca2+ efflux from preloaded cells is followed confirm the influx data but suggest, in addition, that when the influx of extracellular Ca2+ is inhibited, the peptide is able to mobilize Ca2+ from an intracellular location. It is thus concluded that while LH release can be initiated by an increase in the intracellular level of Ca2+, and although LH-RH stimulation does increase the permeability of the plasma membrane to Ca2+, the stimulation of LH release by LH-RH is not dependent upon extracellular Ca2+.

Animals↗

Effect of tyrosine kinase inhibitors on luteinizing hormone-releasing hormone (LHRH)-induced gonadotropin release from the anterior pituitary.

A range of selective tyrosine kinase inhibitors, piceatannol, methyl-2,5-dihydroxycinnamate (MDC), genistein, psi-tectorigenin and lavendustin A, all reduced luteinizing hormone-releasing hormone (LHRH)-induced luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release from pro-oestrous rat hemipituitaries incubated in vitro. In general, both 'initial' release and the augmented release resulting from LHRH self-priming, were reduced in parallel in a concentration-dependent fashion. The effects of piceatannol were independent of the steroidal status of the pituitary tissue. Both piceatannol and MDC greatly reduced LH release by ionomycin and a protein kinase C (PKC) activator, phorbol 12,13-dibutyrate (PDBu), suggesting that the tyrosine kinase(s)-dependent step is in the later stages of the stimulus-secretion pathway activated by the LHRH receptor. These data were supported by immunoblots for phosphotyrosine showing that in the gonadotrope-derived alpha T3-1 cell line, treatment with LHRH caused piceatannol-sensitive increases in specific tyrosine phosphorylation of several proteins (major bands at 65-75 and 120-130 kDa). Treatment of cells with PDBu mimicked the tyrosine phosphorylations evoked by LHRH whereas the PKC inhibitor, GF109203X, partially reduced both LHRH- and PDBu-induced tyrosine phosphorylations. Direct effects of MDC and piceatannol on PKC were assessed in an in vitro PKC assay; piceatannol, but not MDC, inhibited PKC activity but at considerably higher concentrations than required for inhibition of LHRH-induced gonadotropin secretion. These data support a role for tyrosine kinase activation in LHRH-induced secretion.

Animals↗

Inhibitory effects of natural carotenoids, alpha-carotene, beta-carotene, lycopene and lutein, on colonic aberrant crypt foci formation in rats.

Inhibitory effect of four carotenoids prevalent in human blood and tissues against the formation of colonic aberrant crypt foci was examined in Sprague-Dawley rats. They received three intrarectal doses of N-methylnitrosourea in weak 1, and a daily gavage of de-escalated doses of carotenoids during weeks 2 and 5. Lycopene, lutein, alpha-carotene and palm carotenes (a mixture of alpha-carotene, beta-carotene and lycopene) inhibited the development of aberrant crypt foci quantitated at week 6, but beta-carotene did not. The results suggested that lycopene and lutein in small doses may potentially prevent colon carcinogenesis.

Animals↗

Melatonin inhibits luteinizing hormone releasing hormone (LHRH) induction of LH release from fetal rat pituitary cells.

The in vitro effect of melatonin on the release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from fetal rat pituitary cells was investigated. A significant inhibition of LH release induced by 10(-9) M luteinizing hormone releasing hormone (LHRH) was seen when cells were incubated with 10(-9) M melatonin. FSH release was unaffected by either LHRH alone or LHRH in combination with melatonin. In addition, the significant inhibitory effect of melatonin was reduced by pretreatment of the pituitary cells with 10(-10) M melatonin. These findings indicate that melatonin can act directly on the fetal pituitary gland to suppress LHRH-induced release of LH perhaps by a mechanism which eventually involves down-regulation of the melatonin receptors.

Animals↗

Possible resolution of a paradox concerning the use of p-chlorophenylalanine and 5-hydroxytryptophan: evidence for a mode of action involving adrenaline in manipulating the surge of luteinizing hormone in rats.

Various functions involving the central nervous system can be manipulated by the sequential administration of p-chlorophenylalanine and 5-hydroxytryptophan, compounds which respectively inhibit and restore the synthesis of 5-hydroxytryptamine in the brain. An involvement of 5-hydroxytryptamine in the control of a particular function has been considered established when the effect of p-chlorophenylalanine on that function can be overcome by treatment with 5-hydroxytryptophan. This assumption is not, however, invariably substantiated when the functional consequences of other methods of depleting 5-hydroxytryptamine are considered; studies on the control of the daily surge of luteinizing hormone in oestrogen-treated ovariectomized rats present such a paradox. The surge can be prevented by p-chlorophenylalanine and restored by 5-hydroxytryptophan. Nevertheless, neurotoxin-induced lesions of the 5-hydroxytryptamine projections from the raphe nuclei are compatible with a normal occurrence of the surge. We have therefore examined the effects of p-chlorophenylalanine and 5-hydroxytryptophan on hypothalamic monoamines in oestrogen-treated ovariectomized rats and find that the drugs respectively suppress and elevate the concentration of adrenaline in addition to that of 5-hydroxytryptamine. Phenylethanolamine N-methyltransferase, the enzyme responsible for converting noradrenaline to adrenaline, is shown to be inhibited in vivo by p-chlorophenylalanine and in vitro by its metabolite, p-chlorophenylethylamine. The reciprocal effects of p-chlorophenylalanine and 5-hydroxytryptophan on the concentration of adrenaline are of particular interest since drugs which inhibit adrenaline synthesis can block the luteinizing hormone surge. It is proposed that when the 5-hydroxytryptophan-reversible effects of treatment with p-chlorophenylalanine are not reproduced by other procedures which deplete 5-hydroxytryptamine, the significant action of these compounds may involve adrenaline.

5-Hydroxytryptophan↗

beta-Endorphin levels in the cerebrospinal fluid of male talapoin monkeys in social groups related to dominance status and the luteinizing hormone response to naloxone.

beta-Endorphin-like immunoreactivity was measured in the cerebrospinal fluid of 20 male talapoin monkeys living in mixed-sex social groups. It was shown that beta-endorphin was the major immunoreactive peptide; there was no evidence for high molecular weight precursors, or for either N-acetyl or C-shortened metabolites. Dominant males (those at the top of the social hierarchy) had lower levels of beta-endorphin than those of intermediate rank; subordinate males had higher levels than either of the other two ranks--about three times those measured in dominants. There were significant negative correlations between beta-endorphin in cerebrospinal fluid and both the amount of aggression given and sexual behaviour shown towards females. The response of the hypothalamo-pituitary system to opiate blockade was tested by giving the males naloxone in doses of 0.125, 0.25, 0.5, 1.0 and 5.0 mg/kg and assaying serum levels of luteinizing hormone 20 min later. Dominant males released significant amounts of luteinizing hormone at doses of 0.25 and higher; there was no release in either intermediate or subordinate monkeys at any dose. These findings show that an animal's rank in the social group in which it lives is strongly correlated with beta-endorphin levels in the cerebrospinal fluid, and with changes in the neuroendocrine response to opiate blockade. Altered opiate neural activity may be responsible for the depressed levels of sexual behaviour and gonadal function observed in monkeys at the bottom of the hierarchy.

Aggression↗

Abnormal serum prolactin responses to luteinizing hormone-releasing hormone (LHRH) in patients with anorexia nervosa and bulimia.

Abnormal responses of serum prolactin (PRL) to luteinizing hormone-releasing hormone (LHRH) stimulation have been observed in anovulatory women and in hypogonadal patients. Various endocrinological abnormalities have been demonstrated in patients with anorexia nervosa (AN). The present study was undertaken to further investigate responses of serum PRL, growth hormone (GH), luteinizing hormone (LH) and follicle stimulating hormone (FSH) to LHRH stimulation in 65 patients with AN and in 12 patients with bulimia before therapy and in the AN patients after several months of treatment, and in comparison to 12 normal women of the same age. Serum PRL responses to LHRH were positive (peak PRL levels greater than 25 ng/ml and delta increase in PRL greater than 10 ng/ml) in 16.9% of AN and 16.6% of bulimic patients; they were negative (absent) in all controls. Following restoration of the AN patients to normal body weight, the PRL responses to LHRH became normalized in those patients whose eating disorder behavior also returned to normal. However, in those patients whose eating disorder patterns continued to be abnormal, abnormal PRL responses persisted. The bulimic patients were of normal body weight, and yet had abnormal PRL responses. Thus, the responses of PRL correlated more closely with the behavior of the underlying eating disorder rather than with body weight gain or normal body weight.

Adolescent↗

Effects of ovarian hormones on levels of luteinizing hormone in plasma and on serotonin concentrations in discrete brain nuclei.

Levels of serotonin were measureed in microdissected, individual brain nuclei in ovariectomized rats after treatment with ovarian hormones. Regions sampled included nuclei in the forebrain, rostral and medial hypothalamus, and midbrain tegmentum. Estradiol benzoate decreased levels of luteinizing hormone in plasma but did not affect serotonin levels in any region. Progesterone alone elevated serotonin content in the nucleus tractus diagonalis and ventral tegmental area. The combined estrogen plus progesterone regime produced a surge in plasma luteinizing hormone and also markedly elevated serotonin in the median eminence. These results may be of significance for ovarian hormonal regulation of gonadotropin secretion and reproductive behavior.

Animals↗

Response of the bovine corpus luteum to increased secretion of luteinizing hormone induced by exogenous gonadotropin releasing hormone.

Two experiments were conducted to investigate the response of the bovine corpus luteum to surges of luteinizing hormone (LH) induced by natural gonadotropin-releasing hormone (GnRH) administered twice during the same estrous cycle. In experiment 1, eight mature beef cows, each cow serving as her own control, were injected intravenously (iv) with saline on days 2 and 8 of the cycle (day of estrus = day 0 of the cycle), then with 100 micrograms GnRH on days 2 and 8 of the subsequent cycle. Jugular blood samples were taken immediately prior to an injection and at 15, 30, 45, 60, 120 and 240 min postinjection, to quantitate changes in serum luteinizing hormone. Blood was also collected on alternate days after an injection until day 16 of the cycle, to characterize changes in serum progesterone concentrations. Although exogenous GnRH caused release of LH on days 2 and 8 of the cycle, the quantity of LH released was greater on day 8 (P less than .025). Serum levels of progesterone after treatment with GnRH on day 8 of the cycle did not differ significantly from those observed during the control cycles of the heifers. Because exposure of the bovine corpus luteum to excess LH, induced by GnRH early during the estrous cycle, causes attenuated progesterone secretion during the same cycle, these data suggest that a second surge of endogenous LH may ameliorate the suppressive effect of the initial release of LH on luteal function. Duration of the estrous cycle was not altered by treatment (control, 20.4 +/- .5 vs. treated, 20.4 +/- .4 days).(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗

Estradiol and progesterone effects on relative luteinizing hormone and follicle stimulating hormone release induced from superfused anterior pituitary cell cultures by defined LHRH pulse regimens.

These studies examined the capacity of estradiol and progesterone to modulate relative luteinizing hormone (LH) and follicle stimulating hormone (FSH) secretion from superfused anterior pituitary cells when stimulated with luteinizing hormone releasing hormone (LHRH) pulse regimens of specific amplitude, duration and frequency. There was particular interest in whether such steroid and LHRH treatments induced evidence of divergent LH or FSH secretion. Pituitaries were recovered from adult, 2 week ovariectomized rats and cultured for 48 h with collagen coated Cytodex microcarrier beads. Cultures were preincubated either with or without estradiol (1 or 10 nM) for 48 h and were subsequently incubated for 3,6 or 12 h with 100 nM progesterone. All groups were then pulsed with 1 of 3 LHRH regimens; regimen 1 delivered 8 ng in a single 100 microliters bolus once/h; regimen 2 divided the 8 ng dose of regimen 1 into 3 equal doses administered at 4 min intervals thereby maintaining the 8 ng mass of regimen 1 while extending the duration of exposure; regimen 3 was the same as regimen 2 except that the 3 equal doses were administered at a pulse frequency of 1 per 2 h rather than 1 per h thereby not only maintaining the duration of exposure as in regimen 2 but also reducing the pulse frequency. 1 nM estrogen alone for 48 h had no effect on LHRH stimulated LH release regardless of regimen; however, FSH was increased when hourly pulses of increased duration were applied (regimen 2). When estrogen was increased to 10 nM, regardless of regimen, LH was predominantly inhibited while FSH was unaffected. When 1 nM estrogen was followed by progesterone, both LH and FSH were elevated at 6 h progesterone in response to regimen 2; with 10 nM estrogen however, a divergent response was observed in that LH release was elevated at 6 h while FSH was elevated at 3 h in response to regimens 2 and 3. These results first of all confirm that progesterone in combination with estrogen is capable of exerting both inhibitory and stimulatory effects on gonadotropin secretion; secondly, these studies show that, as a direct pituitary effect, the LHRH regimen and the gonadal steroid milieu are capable of interacting to significantly influence the relative secretion of LH and FSH. The data therefore suggest that the divergent gonadotropin secretion seen in various physiological states in vivo is due likely in part to a combination of estrogen and progesterone priming in combination with the hypothalamic LHRH secretory pattern.

Animals↗